Form 4: BioLargo Director Receives New Option Grant Following Expiration of Previous Award

BioLargo director Dennis E. Marshall received a new option grant to purchase 118,422 shares, replacing a previously expired option.

Summary

• BioLargo director Dennis E. Marshall was granted an option to purchase 118,422 shares of common stock at an exercise price of $0.19.
• This new option replaces a previous option for 64,286 shares that recently expired unexercised due to a discrepancy between the original exercise price and the current stock price.
• The new option was granted on December 26, 2024, and expires on December 26, 2034.
• The total number of shares beneficially owned by Mr. Marshall following this transaction is 4,525,941, reflecting the expiration of the previous options.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation adjustment, which is generally neutral to positive. The replacement of the expired option is a positive action, but it's not a major event.

Positives

• The new option grant ensures continued alignment of the director's interests with those of the shareholders.
• The replacement of the expired option demonstrates the company's commitment to compensating its directors.

Management Comments

• The option was granted to replace an expired option due to a discrepancy between the original exercise price and current stock price, pursuant to a plan adopted by the Issuer's Compensation Committee.

Industry Context

The granting of stock options to directors is a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly listed companies, similar to practices at companies like Clean Harbors (CLH) and Waste Management (WM).
• The exercise price of $0.19 is specific to BioLargo's stock price and is not directly comparable to other companies without considering their respective stock valuations.
• The 10-year term of the option is within the typical range for such grants, similar to what might be seen at companies like Tetra Tech (TTEK) or AECOM (ACM).

Stakeholder Impact

• The option grant may have a minor positive impact on shareholder sentiment by aligning director interests with company performance.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

BioLargo, Director, Option Grant, Stock Options, Beneficial Ownership, Compensation, Securities Exchange Act